Ypsomed
Ralph Fasler is an experienced executive in the medical device and healthcare sectors, currently serving as Vice President at Ypsomed AG since January 2020, where responsibility includes leading B2B Contract Manufacturing Insulin Pen operations with P&L oversight. Previously, Ralph held the position of Head of Operations - Healthcare at Amcor for a brief period in 2019 and spent a decade at QIAGEN in various senior director roles, including leadership of Instrument & Software Development and Global Project Management. Responsibilities at QIAGEN encompassed oversight of medical device engineering across multiple locations and management of global operations for lifecycle management of instruments. Prior to QIAGEN, Ralph was Chief Operating Officer at Stoppani AG, leading operations in project management, supply chain management, and quality assurance within the medical devices and semiconductor industries.
This person is not in any teams
This person is not in any offices
Ypsomed
4 followers
Ypsomed Holding AG is a Switzerland-based holding company engaged in the manufacture of injection pens for pharmaceutical and biotech companies. The Company develops and manufactures injection systems for custom-made self-administration, and markets pen needles for the treatment of diabetes, growth disorders or infertility, as well as therapeutic areas. The Company operates two business segments: Injection Systems and Diabetes Care. In the Injection Systems segment, the Company's YDS Ypsomed Delivery Systems offer a range of ready-to-use injection systems for pharmaceutical and biotech companies to administer of drugs or to develop and manufacture them in line with customer requirements. The Diabetes Care segment markets products such as pen needles or insulin pump to diabetics, doctors and health insurance providers. The Company operates its production sites in Burgdorf, Solothurn, Grenchen and Tabor, and sales and distribution network across Europe.